v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 139,071 $ 114,473
Cost of revenue:    
Intangible asset amortization - cost of revenue 2,707 2,585
Total cost of revenue 37,912 34,965
Gross profit 101,159 79,508
Operating expenses:    
Research and development 27,098 17,720
Selling and marketing 27,156 24,454
General and administrative 23,680 33,808
Total operating expenses 78,513 76,604
Income from operations 22,646 2,904
Other income, net 7,328 4,524
Income before income taxes 29,974 7,428
Income tax provision 1,267 381
Net income $ 28,707 $ 7,047
Earnings per share:    
Basic (in USD per share) $ 0.36 $ 0.09
Diluted (in USD per share) $ 0.35 $ 0.09
Shares used to compute earnings per common share:    
Basic (in shares) 79,536,601 78,028,254
Diluted (in shares) 81,313,588 80,056,024
Testing revenue    
Revenue:    
Total revenue $ 135,091 $ 107,309
Cost of revenue:    
Cost of revenue 33,306 28,260
Product revenue    
Revenue:    
Total revenue 3,679 3,580
Cost of revenue:    
Cost of revenue 1,891 1,422
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 301 3,584
Cost of revenue:    
Cost of revenue 8 2,698
Intangible asset amortization - operating expenses    
Operating expenses:    
Intangible asset amortization - operating expenses $ 579 $ 622